Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh ...

In company news, PureTech Health reported US Food & Drug Administration approval for its schizophrenia drug, and abrdn Property Income Trust agreed to sell a subsidiary for GBP351 million. Here is ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...